Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?

CONTEXT Single-nucleotide polymorphisms (SNPs) of the RET protooncogene (RET) could modify disease susceptibility and clinical phenotype in patients with sporadic or familial medullary thyroid carcinoma (FMTC). OBJECTIVE/DESIGN OF THE STUDY: Because frequencies of RET SNPs have not yet been evaluated in patients with elevated serum concentrations of calcitonin (hCt), a biochemical marker for medullary thyroid carcinoma (MTC), we studied RET SNPs in patients with FMTC (n = 22), patients with sporadic MTC (n = 45), and 71 subjects presenting with moderately elevated hCt concentrations (basal, >10 pg/ml; pentagastrin stimulated, > 50 < 100 pg/ml) in comparison with an age- and gender-matched control group (n = 79) with basal hCt concentrations in the normal range (<5 pg/ml). METHODS After DNA extraction from citrated whole blood, RET exons 10, 11, 13, 14, 15, and 16 and exon/intron boundaries were analyzed by PCR-based cycle sequencing for RET germ line mutations, exonic (G691S, L769L, S836S, S904S) and intronic (IVS13+158; NCBI rs2472737 = IVS14-24) SNPs. RESULTS In FMTC patients, the F791Y mutation was found to be associated (P = 0.001) with the L769L SNP. The exonic SNPs (G691S, L769L, S836S, and S904S) were not different among the four groups. The intron 14 SNP (IVS14-24), however, was more frequent in individuals with elevated hCt serum concentrations (P = 0.016) and patients with sporadic MTC (P < 0.001) when compared with the control group. CONCLUSIONS These data suggest that the exon 13 (L769L) and the intron 14 (IVS14-24) SNPs could act as genetic modifiers in the development of some forms of hereditary and sporadic MTC, respectively.

[1]  S. Baumgartner-Parzer,et al.  Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. , 2005, Thyroid : official journal of the American Thyroid Association.

[2]  S. Baumgartner-Parzer,et al.  A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients , 2005, Human Genetics.

[3]  A. Sharp,et al.  RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1 , 2004, Human mutation.

[4]  G. Heinze,et al.  Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. , 2004, Thyroid : official journal of the American Thyroid Association.

[5]  A. Pinchera,et al.  RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  C. Jimenez,et al.  Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[7]  C. Amos,et al.  Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. , 2003, American journal of human genetics.

[8]  Dietmar Roesner,et al.  Novel intronic polymorphisms in the RET proto‐oncogene and their association with Hirschsprung disease , 2003, Human mutation.

[9]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[10]  M. Pierotti,et al.  RET and NTRK1 proto‐oncogenes in human diseases , 2003, Journal of cellular physiology.

[11]  J. Benítez,et al.  Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. , 2003, Cancer research.

[12]  Jurg Ott,et al.  Distribution and characterization of regulatory elements in the human genome. , 2002, Genome research.

[13]  C. Bieglmayer,et al.  Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. , 2002, Wiener klinische Wochenschrift.

[14]  Dietmar Roesner,et al.  Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease , 2002, The Lancet.

[15]  M. Papotti,et al.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma , 2002, Journal of medical genetics.

[16]  F. Waldhauser,et al.  Mutational spectrum of the steroid 21-hydroxylase gene in Austria: identification of a novel missense mutation. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  M. Santoro,et al.  The RET receptor: function in development and dysfunction in congenital malformation. , 2001, Trends in genetics : TIG.

[18]  S. Borrego,et al.  Germline sequence variant S836S in the RET proto‐oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population , 2001, Clinical endocrinology.

[19]  A. von Deimling,et al.  Analysis of the RET,GDNF, EDN3, andEDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease , 2001, Gut.

[20]  M. Wiench,et al.  Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Arlt,et al.  A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation , 2000, Oncogene.

[22]  S. Borrego,et al.  Specific polymorphisms in the RETproto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression , 1999, Journal of medical genetics.

[23]  D. Neuberg,et al.  Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation , 1999, Oncogene.

[24]  F. Raue,et al.  A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[26]  A. Munnich,et al.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. , 1995, Human molecular genetics.

[27]  B. Ponder,et al.  Multiple mRNA isoforms of the human RET proto-oncogene generated by alternate splicing. , 1995, Oncogene.

[28]  A. Pinchera,et al.  Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[29]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[30]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[31]  M. Wiench,et al.  RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. , 2004, Cancer detection and prevention.

[32]  C. Eng.  RET proto-oncogene in the development of human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  V. Rohmer,et al.  Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[34]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .